Details of Drug-Drug Interaction
| Drug General Information (ID: DDI3ETGVU5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Hydroxyurea | Drug Info | Sulfinpyrazone | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antineoplastics | Uricosuric Agents | |||||||
| Structure | |||||||||
| Mechanism of Hydroxyurea-Sulfinpyrazone Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of uricosuric agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Hydroxyurea | Sulfinpyrazone | |||||||
| Mechanism | Anti-uricosuric effects | Uricosuric effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Uricosuric agents | ||||||||
| Factor Description | The beneficial effects of uricosuric agents may be reduced, leading to an increased risk of hyperuricemia and gout. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Monitoring for altered uricosuric efficacy is advisable and dose adjustments of the uricosuric medication may be required. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Cerner Multum, Inc. "Australian Product Information.". | ||||||||||||||||||
| 2 | Product Information. Hydrea (hydroxyurea). Bristol-Myers Squibb, Princeton, NJ. | ||||||||||||||||||